On 19 June 2013, the European Commission announced that it had imposed a fine of € 93.8 million on Danish pharmaceutical group Lundbeck and fines totalling € 52.2 million on several generic medicines producers over their conclusion of so-called “pay-for-delay” agreements intended to hinder the market entry of generic versions of Lundbeck's blockbuster antidepressant Citalopram in the EEA. This is the first time the Commission dealt specifically with these pay-for-delay agreements under the EU competition rules. Following several dawn raids in 2008, 2009 and 2010, the Commission opened a formal investigation into Lundbeck's practices on 7 January 2010 and issued a formal Statement of Objections (“SO”) against Lundbeck and certain generics producers in July 2012. When it opened its
The EU Commission imposes fines totaling up to €145 million on a Danish pharmaceutical group over pay-for-delay agreements (Lundbeck)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.